3:32 PM
 | 
Nov 09, 2017
 |  BC Extra  |  Company News

AZ reports strong China growth in earnings

In its 3Q17 earnings, AstraZeneca plc (LSE:AZN; NYSE:AZN) reported strong growth in the China market despite overall declining product sales. In China, sales were $723 million for the quarter, a 14% increase at constant exchange rates from the prior year, accounting for 15% of AZ's global sales. The pharma reported $4.9 billion in product sales for the quarter, a 2% decrease at constant exchange rates.

In its...

Read the full 311 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >